COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
1 . A method for treatment of chronic lymphocytic leukemia, acute lymphoblastic leukemia or non-Hodgkin's lymphoma in a patient, said method comprising administering to the patient an antibody specific for CD19 wherein said antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6) and a Bruton's tyrosine kinase (BTK) inhibitor.
2 . The method according to claim 1 , wherein the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's, and mantle cell.
3 . The method according to claim 1 , wherein the non-Hodgkin's lymphoma is follicular lymphoma.
4 . The method according to claim 1 , wherein the non-Hodgkin's lymphoma is small lymphocytic lymphoma.
5 . The method according to claim 1 , wherein the non-Hodgkin's lymphoma is mucosa-associated lymphoid tissue.
6 . The method according to claim 1 , wherein the non-Hodgkin's lymphoma is diffuse large B cell lymphoma.
7 . The method according to claim 1 , wherein the non-Hodgkin's lymphoma is Burkitt's lymphoma.
8 . The method according to claim 1 , wherein the non-Hodgkin's lymphoma is mantle cell lymphoma.
9 . The method according to claim 1 , wherein the antibody specific for CD19 and the Bruton's tyrosine kinase (BTK) inhibitor of said combination are administered separately.
10 . The method according to claim 1 , wherein the Bruton's tyrosine kinase (BTK) inhibitor of said combination is administered prior to administration of the antibody specific for CD19.
11 . The method according to claim 1 , wherein the antibody specific for CD19 and the Bruton's tyrosine kinase (BTK) inhibitor of said combination are administered simultaneously.
12 . The method according to claim 1 , wherein the antibody specific for CD19 and the Bruton's tyrosine kinase (BTK) inhibitor of said combination are administered at a time where both drugs are active in the patient at the same time.